Please login to the form below
biosimilars
This page shows the latest biosimilars news and features for those working in and with pharma, biotech and healthcare.
Sandoz’s biosimilar denosumab application accepted by FDA for osteoporosis
Sandoz, a Novartis division, has announced that its biologics licence application for its proposed biosimilar denosumab has been accepted by the US Food and Drug Administration (FDA). ... Human Use (CHMP) last month for a citrate-free high concentration
Latest news
-
Sandoz’s high concentration Hyrimoz formulation recommended for use in EU
Sandoz has received a recommendation from the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) for a citrate-free high concentration formulation (HCF) of its biosimilar Hyrimoz ... Sandoz, which has a total of eight
-
WHO joins calls for equitable access to healthcare products ahead of future pandemics
Sciences, the International Generic and Biosimilar Medicines Association and Médecins Sans Frontières.
-
Sandoz to invest €50m in Austrian manufacturing facility to meet global antibiotic demand
Sandoz, a specialist in generic and biosimilar medicines, has revealed plans for an additional investment of 50m to support the increased European manufacturing capabilities for finished dosage form (FDF) penicillins, the
-
The Holy Grail of healthcare pricing
Drugs that have a generic or biosimilar available. Drugs less than nine years (for small-molecule drugs) or 13 years (for biological products) from their FDA-approval or licensure date.
-
Amgen announces positive results for Solaris biosimilar for paroxysmal nocturnal haemoglobinuria
Amgen has announced positive topline results from a phase 3 study evaluating the safety and efficacy of ABP 959 – a biosimilar candidate to Alexion’s Soliris (eculizumab) – in adult patients with ... We look forward to working with regulators to
More from news
Approximately 145 fully matching, plus 373 partially matching documents found.
Latest Intelligence
-
Biosimilars and beyond: innovating for improved patient outcomes
interchangeability, which supports biosimilar interchangeability – often referred to as switching – for biosimilars approved in Europe. ... Innovation in the biosimilar space. Education and the provision of guidance around treatment with biosimilars
-
Envisioning a healthier every day, for every woman
These three pillars – women’s health, biosimilars and established medicines – are the foundation for how we strive to achieve this vision. ... Most recently, we have entered an agreement with Henlius Biotech, a Shanghai-based global
-
Piloting a route to the biosimilars opportunities in Europe
of biosimilars versus biological innovator originals, but also to increased market competition and the emerging regional or country policies designed to attract more biosimilar treatment alternatives. ... Initially, there were some concerns about the
-
Market shaping for better healthcare decisions
Furthermore, generic medicines, including biosimilars, are increasingly being used to successfully treat more patients.
-
Back to the future
Those models that aim to imitate innovators were diverging between those who followed close behind – such as biosimilars – and those who chose to focus on old science – the unbranded generics, for
More from intelligence
Approximately 15 fully matching, plus 65 partially matching documents found.
Latest appointments
-
Diane DiGangi Trench appointed as country head of Sandoz UK
In her new role, she will work to continue to expand access to biosimilar, generic and originator drugs for patients in the UK. ... anniversary of the launch of Sandoz’s first biosimilar medicine approved for use in the UK, the company said in a
-
New hires at Bayer, Eisai and Accord Healthcare
and biosimilar specialists,” he added.
-
Ashfield, Health Unlimited and Ashley Communications add to their teams
Van Weperen was most recently at diabetes giant Novo Nordisk, where he worked on delivering insulin and GLP1 biosimilar defence strategies, leading Novo’s UK diabetes team.
-
Lilly bolsters its oncology team
Furthermore, she has been on the forefront of research in oncology vaccines, immuno-oncology and biosimilars, giving her the unique expertise that will be pivotal in helping us continue to develop
-
PharmaLex appoints Zabin Younes as associate director
She joins the group as an associate director and arrives from ERA Consulting - a biopharmaceutical consultancy based in the UK - where she picked up experience in the biosimilar development lifecycle. ... With experience spanning over 15 years, Younes’
More from appointments
Approximately 1 fully matching, plus 16 partially matching documents found.
Latest from PMHub
-
Impact Medical Education
In addition to providing a broad range of medical communication offerings, we have a particular specialism in launching and supporting biosimilars at a global, regional, and country level.
-
Freyr Solutions
for Pharmaceutical, Generics, Medical Device, biotechnology, Biosimilar, Consumer Healthcare, Cosmetic companies across the globe.
-
Market Shaping for Better Healthcare Decisions
Furthermore, generic medicines, including biosimilars, are increasingly being used to successfully treat more patients.
-
Integrated NHS finances: what do they mean for High Cost Drugs?
contracts. Therefore, the price of a High Cost Drug will be very significant within the overall price of a procedure, and cheaper biosimilars that can save more in direct costs are ... This is going to drive major reconfiguration across all pathways.
-
>> FAST FORWARD How pandemics accelerate new thinking and early adoption in healthcare.
And biosimilars, have provided access to a consistent and affordable supply for patients during these times of unprecedented demand.
More from PMHub
Approximately 10 fully matching, plus 31 partially matching documents found.
Subscribe to our email news alerts
-
Senior Medical Writer
- Highly competitive salary
- Early Access Program - Regulatory Affairs (EAP-RA)
- Highly competitive salary
- Strategy Director - Healthcare Advertising
- Highly competitive salary
-
Technical Sales Representative
- Highly competitive salary
-
Pharmacovigilance Project Lead
- Highly competitive salary
- Associate Director - Global Healthcare Consulting
- Highly competitive salary
-
Pharmacovigilance Manager
- Highly competitive salary
-
Omnichannel Account Director
- £55,000 - £65,000 yearly
- MHRA to introduce new UK clinical trials framework
- AbbVie’s Parkinson’s disease therapy application rejected by FDA
- Roche and Eli Lilly to collaborate on Alzheimer’s disease blood test
- Takeda presents positive phase 2b results for TAK-279 in plaque psoriasis
- FDA proposes improvements for oncology clinical trials supporting accelerated approval
- Novo Nordisk and Dewpoint partner on insulin resistance drug candidates
- PMGroup announces launch of new recruitment platform PharmaRole
- Merck reports positive results for Keytruda plus chemotherapy in endometrial cancer
- BioNTech reveals plans to spend about €1bn more on research and development this year
- AstraZeneca’s mild combination asthma reliever approved in UK
- Virtual Patient Engagement Program: A Customer Story
- Putting Skin in the Game at AAD 2023
- Locus Biosciences announces first patient treated in urinary tract infection trial
- Team ITG appoints Gerhard Arnhofer as head of customer strategy for life sciences division
- Merck reports positive results for Keytruda plus chemotherapy in endometrial cancer
- Takeda presents positive phase 2b results for TAK-279 in plaque psoriasis
- Sanofi/Regeneron’s Dupixent approved by EC for atopic dermatitis in children
- Inizio appoints Stefanie Christmas as global head of DE&I
PMHub
Dovetail
We’re a specialist health consultancy that supports companies, healthcare professionals and patients to work hand in hand with a common...
Latest intelligence
- Virtual Patient Engagement Program: A Customer Story
- Our client wanted to better understand the needs, preferences, and treatment gaps among adult patients with a rare genetic disease......
- Humancomms for humancare?
- Paul Hutchings, founder of fox&cat, writes on the role of humour in healthcare comms: PharmaComms 2023...
- Rare diseases: not so rare after all
- The brave new world addressing rare diseases – a way ahead to better and more inclusive treatment...
